



## Talwin™ (pentazocine) – Product discontinuation

- On April 16, 2018, the [FDA announced](#) the discontinuation of Hospira's [Talwin \(pentazocine\) 30 mg/mL injection](#).
  - The product discontinuation is not due to product quality, safety or efficacy concerns.
- Talwin is indicated for the management of pain and used as a preoperative or preanesthetic and as a supplement for surgical anesthesia.
  - Talwin is a Schedule IV controlled substance.
  - Because of the risks of addiction, abuse, and misuse, reserve Talwin for use in patients for whom alternative treatment options have not been tolerated or have not provided adequate analgesia.
- Talwin carries boxed warnings for risks of addiction, abuse, and misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and risks of profound sedation for concomitant use with benzodiazepines or other central nervous system depressants.
- There are currently no generic manufacturers of this product.
- For additional questions, contact Hospira (now Pfizer injectables) at **1-844-646-4398**.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.